



## **ZAI Lab announces a global licensing agreement with Sanofi for a novel compound to potentially treat NSCLC**

*Shanghai (31/07/2015)* - ZAI Lab Limited (ZAI Lab), an innovative biotech company based in China, announced today that it has entered into a global licensing agreement with Sanofi for a novel multi-kinase inhibitor for the potential treatment of non-small cell lung cancer and other oncology indications.

Under the terms of the agreement, ZAI Lab will be responsible for global development, manufacturing and commercialization of this novel product. Sanofi will potentially receive development and regulatory approval milestones and tiered royalties from the global net sales of the licensed product. Additional terms of the agreement were not disclosed.

Dr. Samantha Du, founder and CEO of ZAI Lab said: “NSCLC is a serious disease with large patient population and unmet medical needs in the world, especially in China. We are very excited to partner with Sanofi on this innovative program that may significantly improve patients’ survival outlook and quality of life.”

### **About Non-Small Cell Lung Cancer**

Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 85% of lung cancers are non-small cell lung cancers (NSCLC), the main types of which are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC presents significant public health problems for nearly every country, largely due to the fact that diagnosis generally happens in the advanced stages, and also because of the high death rate associated with the disease.

Since 1985, lung cancer has been the most common cancer worldwide. According to estimates by the World Health Organization, there were more than 1.8 million new cases of lung cancer and nearly 1.6 million deaths worldwide due to lung cancer in 2012. The high case fatality rate indicates that lung cancer incidence and lung cancer mortality are similar. In China, lung cancer is the largest and also one of the fastest growing cancers with annual incidence of over 600,000 patients. This is primarily due to the large Chinese smoking population and also long term exposure to other cancer-causing substances including air pollution

### **About ZAI Lab**

ZAI Lab is a leading biotech company based in China focused on discovering and developing innovative medicines for unmet medical needs globally. The company is building a strong portfolio of therapeutic programs aimed at transforming patients’

lives. Zai Lab has a world class leadership team with deep experience at global pharmaceutical and biotech organizations. The team has a strong track record of success – successfully taken five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug research and development powerhouse with a culture of excellence and teamwork and a strong focus on fostering innovation and creativity.

For more information, please visit [www.zailaboratory.com](http://www.zailaboratory.com)

For media enquiries, please contact:

ZAI Lab

Jonathan Wang, +86 21 6163 2587

[jwang@zailaboratory.com](mailto:jwang@zailaboratory.com)